Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 24 2025
0mins
Source: Globenewswire
Company Announcement: Perspective Therapeutics, Inc. announced that updated data on their radiopharmaceutical program [^212Pb]VMT-α-NET will be presented at the ESMO Congress 2025, focusing on targeted alpha-particle therapy for advanced neuroendocrine tumors.
Company Overview: The company is developing innovative cancer treatments using the alpha-emitting isotope ^212Pb and aims to personalize treatment through complementary imaging diagnostics, with ongoing clinical trials for various cancer types in the U.S.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
